Andres F. Cardona
@AndresFCardonaZ
Pursue knowledge, mentor students, collaborate globally, and push boundaries. Everything else is just noise in the academic concert.
ID:1049075800996286464
07-10-2018 23:15:36
21,3K Tweets
7,6K Followers
3,9K Following
Follow People
Immune checkpoint blockers in pts with solid organ transplant and solid tumors. Potential treatm for some pts but limited activity for pts with SOT and 🫁cancer.1/3 have organ rejection within 2mo after treatment initiation.Thanks all authors! OncoAlert
authors.elsevier.com/sd/article/S20…
New #OpenAccess study suggest that neoadjuvant platinum-based ICI-chemo. for those with early-stage #NSCLC is associated with improvements in 2-year EFS and pCR 🫁
See the full study in JAMA Network Open by Giuseppe Banna, Mona Hassan, Alfredo Addeo MD & colleagues ⬇️
jamanetwork.com/journals/jaman…
Pooled 5-yr outcomes of Pembro+Chemo for PDL1<1% metastatic NSCLC JTO & JTO CRR:
- 442pts (KN189, KN407 &China/Japan extensions)
- mOS 0.64, mPFS HR 0.66, 5yr OS 12.5 v 9.3% favors chemo-IO
- g3+ TRAEs 59.1% chemo-IO
IASLC OncoAlert Shirish Gadgeel
#LCSM
jto.org/article/S1556-…
Novel EGFR germline mutation in an individual with lung cancer. Germline mutations in lung cancer is a developing paradigm with the potential to change screening guidelines.
Himil Mahadevia Janakiraman Subramanian Saint Luke's Cancer Institute Ben Ponvilawan Clinical Lung Cancer
clinical-lung-cancer.com/article/S1525-…